Oxcarbazepine Tablet, Film Coated
Product Images NDC 60429-062

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 60429-062). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

60429 061 05lb

OXCARBAZEPINE is a medication available in tablet form, with a strength of 150mg. The package contains 500 tablets. Dosage information is provided in the package insert. A medication guide from Pharmagrt is also provided to the patient and can be printed at https://igsms.us/. The tablets should be stored at a temperature between 20°C and 25°C (68°F-77°F), with excursions permitted between 15°C and 30°C (59°F-86°F). The rest of the text appears to be gibberish.*

FDA Label Image

60429 062 05lb

This is a description for a medication called OXCARBAZEPINE, which is available in the form of tablets. The package contains 500 tablets with a strength of 300 mg. The text also includes a reference to a medication guide that needs to be printed for each patient. No further useful information could be obtained from the text.*

FDA Label Image

60429 063 05lb

This is a pharmaceutical label for Oxcarbazepine Tablets. The NDC code, dosage strength, and quantity are provided. The medication should be stored in a tight container and kept away from children. Manufacturing and packaging information is also provided.*

FDA Label Image

Oxcarbazepine 01

FDA Label Image

Oxcarbazepine 02

The text provides the results of a Tog-rank test with a p-value of 0.0001. Additionally, there is a chart with two rows displaying 'T' characters and numbers 0-9, and two columns labeled 'Day2' and 'Day11' with times of 8am for each. The chart also shows two treatment groups: Oxcarbazepine and Placebo. No further information is available.*

FDA Label Image

Oxcarbazepine 03

The text describes the seizure rate for two treatment groups, Oxcarbazepine and Placebo, over a period of time. The log-rank test resulted in a p-value of 0.046, suggesting a significant difference between the two groups. The x-axis represents the number of days from the first dose to the first seizure, while the y-axis shows the number of seizures.*

FDA Label Image

Oxcarbazepine 04

FDA Label Image

Oxcarbazepine 05

This appears to be a survival plot depicting the cumulative survival of two groups (HIGH and LOW) over a specified period. The graph shows the percentage of surviving participants at different time points ranging from 0 to 130 days. The log-rank test was employed to compare the survival curves of both groups and the p-value was found to be 0.0001.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.